These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Comparative inhibition of inducible and constitutive CYPs in rat hepatic microsomes by parathion. Murray M; Butler AM Xenobiotica; 2004 Aug; 34(8):723-39. PubMed ID: 15690761 [TBL] [Abstract][Full Text] [Related]
23. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes. Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730 [TBL] [Abstract][Full Text] [Related]
24. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Yamazaki H; Shimada T Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18. Minoletti C; Dijols S; Dansette PM; Mansuy D Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023 [TBL] [Abstract][Full Text] [Related]
26. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Lasker JM; Wester MR; Aramsombatdee E; Raucy JL Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596 [TBL] [Abstract][Full Text] [Related]
27. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Yamazaki H; Shimada T Xenobiotica; 1999 Mar; 29(3):231-41. PubMed ID: 10219964 [TBL] [Abstract][Full Text] [Related]
28. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Yamazaki H; Shibata A; Suzuki M; Nakajima M; Shimada N; Guengerich FP; Yokoi T Drug Metab Dispos; 1999 Nov; 27(11):1260-6. PubMed ID: 10534310 [TBL] [Abstract][Full Text] [Related]
29. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Eagling VA; Tjia JF; Back DJ Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822 [TBL] [Abstract][Full Text] [Related]
30. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160 [TBL] [Abstract][Full Text] [Related]
31. 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Huang Z; Guengerich FP; Kaminsky LS Carcinogenesis; 1998 May; 19(5):867-72. PubMed ID: 9635876 [TBL] [Abstract][Full Text] [Related]
32. Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. Jean P; Lopez-Garcia P; Dansette P; Mansuy D; Goldstein JL Eur J Biochem; 1996 Nov; 241(3):797-804. PubMed ID: 8944768 [TBL] [Abstract][Full Text] [Related]
33. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Hyland R; Roe EG; Jones BC; Smith DA Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070 [TBL] [Abstract][Full Text] [Related]
34. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Masubuchi Y; Horie T Chem Res Toxicol; 1999 Oct; 12(10):1028-32. PubMed ID: 10525281 [TBL] [Abstract][Full Text] [Related]
35. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. Yamazaki H; Gillam EM; Dong MS; Johnson WW; Guengerich FP; Shimada T Arch Biochem Biophys; 1997 Jun; 342(2):329-37. PubMed ID: 9186495 [TBL] [Abstract][Full Text] [Related]
36. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Giancarlo GM; Venkatakrishnan K; Granda BW; von Moltke LL; Greenblatt DJ Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587 [TBL] [Abstract][Full Text] [Related]
37. Metabolic activation of o-phenylphenol to a major cytotoxic metabolite, phenylhydroquinone: role of human CYP1A2 and rat CYP2C11/CYP2E1. Ozawa S; Ohta K; Miyajima A; Kurebayashi H; Sunouchi M; Shimizu M; Murayama N; Matsumoto Y; Fukuoka M; Ohno Y Xenobiotica; 2000 Oct; 30(10):1005-17. PubMed ID: 11315102 [TBL] [Abstract][Full Text] [Related]
38. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Gallagher EP; Kunze KL; Stapleton PL; Eaton DL Toxicol Appl Pharmacol; 1996 Dec; 141(2):595-606. PubMed ID: 8975785 [TBL] [Abstract][Full Text] [Related]
39. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Ball SE; Ahern D; Scatina J; Kao J Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822 [TBL] [Abstract][Full Text] [Related]
40. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. Nielsen TL; Rasmussen BB; Flinois JP; Beaune P; Brosen K J Pharmacol Exp Ther; 1999 Apr; 289(1):31-7. PubMed ID: 10086984 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]